ArticleActa neurochirurgica2026
Giant pituitary adenomas: an institutional experience with 289 surgically treated patients.
Article in Acta neurochirurgica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGiant pituitary adenomas (GPA) are considered difficult to treat and the operative procedures are associated with more complications. This study aimed to assess treatment strategies of GPAs in a large consecutive and uniformly documented series in a single specialized center.
methodsA total of 289 patients with GPA who underwent primary surgery in our department between December 1982 and December 2022 were analyzed in this retrospective study. GPAs were defined by a maximum diameter of ≥ 4 cm in at least one plane. Patients were reviewed for endocrine, radiological and ophthalmological outcomes as well as complication and mortality rates.
resultsThe mean maximum tumor diameter was 4.6 ± 0.7 cm. 201 patients (69.6%) underwent transsphenoidal and 36 patients (12.4%) underwent transcranial surgery only. 52 patients (18.0%) underwent a combined approach within a few weeks. Gross-total resection (GTR) was achieved in one-fifth (n = 52) of the patients. It was dependent, among other factors, on patients' tumor size and tumor extension. Severe complications such as tumor apoplexy, meningitis or cerebrospinal fluid leaks occurred in 5.9%, 3.5% and 2.8% of patients, respectively. Seven deaths (2.4%) occurred in the early postoperative period. The median follow-up time was 76 months, at which point 70.2% of patients showed a stable condition without requiring further treatment.
conclusionGenerally, the treatment of giant pituitary adenomas remains a significant challenge. Although the transsphenoidal approach achieved good results, tumor size and configuration often required a transcranial approach or a combination of different approaches. It is important to consider individual patient and tumor characteristics when selecting the most appropriate surgical approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.